Systemic Juvenile Idiopathic Arthritis Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Systemic Juvenile Idiopathic Arthritis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type (Drug Treatment {Anti-inflammatories (NSAIDS), Tumor Necrosis Factor (TNF) Blockers, Muscle Relaxants, Immune Suppressants Drugs, Disease Modifying Antirheumatic Drugs, Others}, Biologics, Other), By Route of Administration (Oral, Injectables, Other), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The Global Systemic Juvenile Idiopathic Arthritis Market is projected to expand from USD 1.93 Billion in 2025 to USD 2.31 Billion by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 3.04%. Systemic Juvenile Idiopathic Arthritis (sJIA) is a rare autoinflammatory condition marked by daily fevers, distinctive rashes, and widespread inflammation affecting both joints and internal organs. The market's growth is predominantly fueled by the ongoing development of advanced targeted biologic therapies and enhanced diagnostic protocols that facilitate earlier clinical intervention. The Arthritis Foundation estimated that in 2024, approximately 3 million children and young adults worldwide were affected by juvenile idiopathic arthritis, highlighting a significant patient population and a substantial demand for effective management strategies, especially for severe subtypes like sJIA.
However, the sector faces a significant hurdle due to the exceedingly high costs associated with advanced biologic medications. These considerable financial burdens pose barriers to patient accessibility and strain healthcare budgets, consequently impeding the broader expansion of the market.
Market Driver
The increasing adoption of interleukin-1 (IL-1) and interleukin-6 (IL-6) inhibitors is fundamentally transforming the clinical management of systemic juvenile idiopathic arthritis (sJIA). These targeted biologic therapies precisely address the cytokine storms responsible for the disease’s severe autoinflammatory symptoms, offering more effective, long-term disease control than traditional corticosteroids. This strategic shift towards precision medicine has significantly boosted commercial growth for proprietary biologic formulations; for instance, Novartis reported in October 2024 that global sales of Ilaris (canakinumab), a key IL-1 beta inhibitor for sJIA, reached USD 372 million in Q3 2024, a 12% year-over-year increase. This robust revenue performance underscores the critical reliance on advanced biologics to manage this complex condition, especially given that sJIA accounted for an estimated 10% to 20% of all juvenile idiopathic arthritis cases in 2024, driving disproportionate demand for these specialized treatments.
Concurrently, the market is experiencing a notable structural evolution driven by the introduction of cost-effective biosimilars, which are progressively removing financial barriers to access. As patents for original biologics expire, the entry of biosimilar alternatives fosters greater market competition and alleviates the economic strain on healthcare systems, thereby broadening patient reach. A significant development occurred in April 2024 with Fresenius Kabi’s announcement of the U.S. launch of Tyenne, a tocilizumab biosimilar, which uniquely received regulatory approval for both intravenous and subcutaneous administration. This product offers unprecedented flexibility and affordability for patients requiring chronic IL-6 receptor antagonist therapy. This proliferation of biosimilars is anticipated to sustain market volume growth by making life-altering sJIA treatments more accessible to a wider pediatric population previously constrained by the prohibitive costs of originator drugs.
Market Challenge
The prohibitive costs associated with advanced biologic medications represent a primary impediment to the expansion of the Global Systemic Juvenile Idiopathic Arthritis Market. These elevated financial requirements compel healthcare payers and insurance providers to implement stringent cost-containment measures, such as prior authorization and step therapy protocols. As a result, the high price effectively disconnects clinical demand from actual market revenue, since administrative hurdles frequently delay or deny patient access to these essential treatments. This environment of financial scrutiny limits the addressable patient pool and creates a significant bottleneck in the adoption of premium therapies.
This challenge is further quantified by recent industry data underscoring the severity of access barriers. The American College of Rheumatology reported in 2025 that approximately 89% of rheumatologists regularly encountered delays in patient access to prescribed treatments due to insurance barriers like prior authorization. Such high rates of administrative interference directly restrict the volume of biologic prescriptions that are successfully filled and reimbursed. By obliging patients to navigate complex approval processes or first try cheaper alternatives, these economic barriers significantly dampen the market’s potential for broader growth and revenue generation.
Market Trends
The emergence of Janus kinase (JAK) inhibitors as alternative treatment options is transforming the therapeutic landscape for systemic juvenile idiopathic arthritis (sJIA), particularly for patients who do not respond to standard biologic regimens. This trend is driven by a growing clinical need for effective oral interventions to manage complex cases involving life-threatening complications, such as interstitial lung disease, where traditional monoclonal antibodies may show limited efficacy. Highlighting this significant shift in clinical strategy, Medscape reported in December 2024 that analysis of patient data revealed 57.1% of patients with sJIA-associated lung disease had used tofacitinib, compared to only 5.7% of those without this complication. This data underscores the critical expansion of the market toward small molecule inhibitors to address high-risk patient subgroups who remain underserved by first-line therapies.
Simultaneously, the sector is witnessing advancements in novel cytokine-targeted therapies beyond IL-1 and IL-6, specifically focusing on interferon-gamma (IFN-y) inhibition to manage macrophage activation syndrome (MAS), a severe sJIA complication. This development represents a move toward agents that offer more precise control over the hyperinflammatory cytokine storms often resistant to existing biologic controls. Evidencing the growing commercial traction of this distinct mechanism, Sobi reported in its Q2 2024 Quarterly Report in July 2024 that global revenue for Gamifant, a targeted interferon-gamma blocking antibody used in these hyperinflammatory contexts, reached SEK 522 million for the quarter. This revenue growth indicates a strategic diversification in the therapeutic arsenal, validating the market's progression toward novel targets that offer life-saving outcomes for the most acute forms of systemic autoinflammation.
Key Market Players
* Novartis AG
* F. Hoffmann-La Roche Ltd.
* Pfizer Inc.
* Johnson & Johnson
* AbbVie Inc.
* Bristol-Myers Squibb Company
* Eli Lilly and Company
* Sanofi S.A.
* Amgen Inc.
* Regeneron Pharmaceuticals, Inc.
Report Scope
In this report, the Global Systemic Juvenile Idiopathic Arthritis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Systemic Juvenile Idiopathic Arthritis Market, By Treatment Type
* Drug Treatment
* Biologics
* Other
# Systemic Juvenile Idiopathic Arthritis Market, By Route of Administration
* Oral
* Injectables
* Other
# Systemic Juvenile Idiopathic Arthritis Market, By Distribution Channel
* Hospital Pharmacies
* Retail Pharmacies
* Online Pharmacies
# Systemic Juvenile Idiopathic Arthritis Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Systemic Juvenile Idiopathic Arthritis Market.
Available Customizations:
Global Systemic Juvenile Idiopathic Arthritis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Systemic Juvenile Idiopathic Arthritis Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Treatment Type (Drug Treatment {Anti-inflammatories (NSAIDS), Tumor Necrosis Factor (TNF) Blockers, Muscle Relaxants, Immune Suppressants Drugs, Disease Modifying Antirheumatic Drugs, Others}, Biologics, Other)
5.2.2. By Route of Administration (Oral, Injectables, Other)
5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
5.2.4. By Region
5.2.5. By Company (2025)
5.3. Market Map
6. North America Systemic Juvenile Idiopathic Arthritis Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Treatment Type
6.2.2. By Route of Administration
6.2.3. By Distribution Channel
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Systemic Juvenile Idiopathic Arthritis Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Treatment Type
6.3.1.2.2. By Route of Administration
6.3.1.2.3. By Distribution Channel
6.3.2. Canada Systemic Juvenile Idiopathic Arthritis Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Treatment Type
6.3.2.2.2. By Route of Administration
6.3.2.2.3. By Distribution Channel
6.3.3. Mexico Systemic Juvenile Idiopathic Arthritis Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Treatment Type
6.3.3.2.2. By Route of Administration
6.3.3.2.3. By Distribution Channel
7. Europe Systemic Juvenile Idiopathic Arthritis Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Treatment Type
7.2.2. By Route of Administration
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Systemic Juvenile Idiopathic Arthritis Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Treatment Type
7.3.1.2.2. By Route of Administration
7.3.1.2.3. By Distribution Channel
7.3.2. France Systemic Juvenile Idiopathic Arthritis Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Treatment Type
7.3.2.2.2. By Route of Administration
7.3.2.2.3. By Distribution Channel
7.3.3. United Kingdom Systemic Juvenile Idiopathic Arthritis Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Treatment Type
7.3.3.2.2. By Route of Administration
7.3.3.2.3. By Distribution Channel
7.3.4. Italy Systemic Juvenile Idiopathic Arthritis Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Treatment Type
7.3.4.2.2. By Route of Administration
7.3.4.2.3. By Distribution Channel
7.3.5. Spain Systemic Juvenile Idiopathic Arthritis Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Treatment Type
7.3.5.2.2. By Route of Administration
7.3.5.2.3. By Distribution Channel
8. Asia Pacific Systemic Juvenile Idiopathic Arthritis Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Treatment Type
8.2.2. By Route of Administration
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Systemic Juvenile Idiopathic Arthritis Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Treatment Type
8.3.1.2.2. By Route of Administration
8.3.1.2.3. By Distribution Channel
8.3.2. India Systemic Juvenile Idiopathic Arthritis Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Treatment Type
8.3.2.2.2. By Route of Administration
8.3.2.2.3. By Distribution Channel
8.3.3. Japan Systemic Juvenile Idiopathic Arthritis Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Treatment Type
8.3.3.2.2. By Route of Administration
8.3.3.2.3. By Distribution Channel
8.3.4. South Korea Systemic Juvenile Idiopathic Arthritis Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Treatment Type
8.3.4.2.2. By Route of Administration
8.3.4.2.3. By Distribution Channel
8.3.5. Australia Systemic Juvenile Idiopathic Arthritis Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Treatment Type
8.3.5.2.2. By Route of Administration
8.3.5.2.3. By Distribution Channel
9. Middle East & Africa Systemic Juvenile Idiopathic Arthritis Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Treatment Type
9.2.2. By Route of Administration
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Systemic Juvenile Idiopathic Arthritis Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Treatment Type
9.3.1.2.2. By Route of Administration
9.3.1.2.3. By Distribution Channel
9.3.2. UAE Systemic Juvenile Idiopathic Arthritis Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Treatment Type
9.3.2.2.2. By Route of Administration
9.3.2.2.3. By Distribution Channel
9.3.3. South Africa Systemic Juvenile Idiopathic Arthritis Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Treatment Type
9.3.3.2.2. By Route of Administration
9.3.3.2.3. By Distribution Channel
10. South America Systemic Juvenile Idiopathic Arthritis Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Treatment Type
10.2.2. By Route of Administration
10.2.3. By Distribution Channel
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Systemic Juvenile Idiopathic Arthritis Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Treatment Type
10.3.1.2.2. By Route of Administration
10.3.1.2.3. By Distribution Channel
10.3.2. Colombia Systemic Juvenile Idiopathic Arthritis Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Treatment Type
10.3.2.2.2. By Route of Administration
10.3.2.2.3. By Distribution Channel
10.3.3. Argentina Systemic Juvenile Idiopathic Arthritis Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Treatment Type
10.3.3.2.2. By Route of Administration
10.3.3.2.3. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Systemic Juvenile Idiopathic Arthritis Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Novartis AG
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. F. Hoffmann-La Roche Ltd.
15.3. Pfizer Inc.
15.4. Johnson & Johnson
15.5. AbbVie Inc.
15.6. Bristol-Myers Squibb Company
15.7. Eli Lilly and Company
15.8. Sanofi S.A.
15.9. Amgen Inc.
15.10. Regeneron Pharmaceuticals, Inc.
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們